Investigating how BMPR2 mutations contribute to pulmonary arterial hypertension
BMPR2 mutations, Neointimal Transformation and Pulmonary Arterial Hypertension
['FUNDING_OTHER'] · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · NIH-10881720
This study is looking at how changes in the BMPR2 gene might contribute to pulmonary arterial hypertension (PAH) in veterans with heart and lung problems, using a rat model to find out how these changes and inflammation affect blood vessels, with the hope of discovering new treatments that could help patients with these genetic mutations.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VETERANS ADMIN PALO ALTO HEALTH CARE SYS (nih funded) |
| Locations | 1 site (PALO ALTO, UNITED STATES) |
| Trial ID | NIH-10881720 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of BMPR2 gene mutations in the development of pulmonary arterial hypertension (PAH), a serious condition affecting veterans with chronic cardiopulmonary issues. By using a rat model that mimics human disease, the study examines how these mutations, combined with inflammation, lead to severe vascular changes. The research aims to identify the mechanisms behind neointimal transformation and explore potential therapies, such as TGF-b blockade, that could improve patient outcomes. Patients with these genetic mutations may benefit from insights gained through this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are veterans with chronic cardiopulmonary conditions who carry BMPR2 mutations.
Not a fit: Patients without BMPR2 mutations or those not suffering from pulmonary arterial hypertension may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve survival rates for patients with pulmonary arterial hypertension.
How similar studies have performed: Previous research has shown promising results in understanding the mechanisms of pulmonary arterial hypertension and the role of genetic mutations, indicating that this approach has potential for success.
Where this research is happening
PALO ALTO, UNITED STATES
- VETERANS ADMIN PALO ALTO HEALTH CARE SYS — PALO ALTO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NICOLLS, MARK ROBERT — VETERANS ADMIN PALO ALTO HEALTH CARE SYS
- Study coordinator: NICOLLS, MARK ROBERT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.